Clinical trial · Interventional
Immunonutrition Supplementation in Head and Neck Cancer Patients Undergoing Cancer Treatment Study
Head and Neck Cancer Immunonutrition Supplementation During Cancer Treatment: A Randomized, Open-label Intervention Study
NCT05526040CI-TRIAL-00060660HaNISunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, randomized, open-label intervention study to evaluate the effectiveness of immunonutrition supplementation in head and neck cancer (HNC) patients during cancer treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunonutrient-enriched oral nutrition supplementation | Dietary Supplement | — | UNRESOLVED |
| Standard medical nutrition therapy | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention
- description
- Standard medical nutrition therapy with Immunonutrition
- interventionNames
- Dietary Supplement: Immunonutrient-enriched oral nutrition supplementation
- type
- ACTIVE_COMPARATOR
- label
- Control
- description
- Standard medical nutrition therapy
- interventionNames
- Dietary Supplement: Standard medical nutrition therapy
Primary outcomes (3)
- measure
- Body weight (kilograms)
- timeFrame
- Baseline, weekly review during cancer treatment, 1month post-completion of cancer treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent obtained * Adult HNC patients, male or female, above 18 years of age * Primary HNC diagnosis, stage I to III; including: cancer of the nasopharynx, oropharynx, oral cavity, hypopharynx, or larynx, etc. * Referred and planned for curative-intent cancer treatment (radiotherapy and chemotherapy) * Eastern Cooperative Oncology Group (ECOG) performance status \< 2 Exclusion Criteria: * Inability or unwillingness to provide written informed consent or comply with the requirements of the protocol * Patients with metastatic stage or recurring/relapse of cancer at same site * Planned for palliative cancer treatment * Underlying severe hepatic failure or renal dysfunction (eGFR \< 30ml/min/1.73m2) * Underlying severe sepsis, neutropenia, immune-deficiencies or autoimmune diseases * Consumption of supplements or enriched foods containing immunonutrients (omega- 3, arginine or nucleotides) in the previous month prior to study; including dietary supplements such as: fish oil capsules, arginine tablets/powder, RNA capsules, etc. * Known allergy or intolerance to components of the immunonutrition supplement (cow's milk, fish or soy) * Enrolment in other cancer treatment trials
References
Publications (0)
Data not yet available
No reference posted for this study.